近日，由华中科技大学牵头，奥精医疗（688613.SH）深度参与的"高活性骨修复材料关键新技术及应 用"项目，凭借技术原创性、产业开拓性以及显著的临床转化价值，荣获中国生物材料学会科学技术一 等奖。 人工骨修复材料是中国生物材料领域较早实现产业转化的一类医疗器械产品，奥精医疗创始人崔福斋教 授团队通过对天然骨组织的充分研究，通过模拟骨组织在体内矿化发育的过程，发展出体外仿生矿化技 术，首次给出直接证据支持了矿化胶原的理论，为仿生工程新功能材料的研究指明了方向。在科学研究 的基础上，崔福斋教授团队将此技术进行了产业转化，开发多项III类医疗器械产品。产品广泛应用于骨 免责声明：此文内容为本网站刊发或转载企业宣传资讯，仅代表作者个人观点，与本网无关。文章不构 成投资建议，仅供读者参考，并请自行核实相关内容。 2025年，由华中科技大学张胜民教授牵头，与奥精医疗创始团队以"高活性骨修复材料关键新技术及应 用"共同申报中国生物材料学会科学技术奖，并获得一等奖的殊荣，是对参与申报的各方在科学基础研 究和技术转化方面的充分肯定。 作为深度参与方，此次获奖是对于奥精医疗在高活性骨修复材料领域的技术引领性充分认可。奥精医疗 ...

Core Viewpoint - The article provides a comprehensive overview of the Chinese biomedical materials industry, highlighting key listed companies, their business segments, revenue projections, and strategic planning for future growth. Group 1: Overview of Listed Companies - The A-share listed companies in the biomedical materials sector include Guocera Materials, Weigao Orthopedics, Haohai Biological Technology, Lepu Medical, Lanfang Medical, and Xinmai Medical [1] - The industry is characterized by a diverse range of companies focusing on various segments such as biocomposite materials, biopolymers, and biometals [2][3] Group 2: Revenue Projections - For 2024, key revenue figures for selected companies include: - Guocera Materials: 40.47 billion CNY from dental ceramics and biomedical materials [4] - Weigao Orthopedics: 14.51 billion CNY from orthopedic implants [10] - Lepu Medical: 61.03 billion CNY from cardiovascular materials [5] - The overall revenue for the biomedical materials sector is projected to grow, driven by increasing demand for advanced medical solutions [11] Group 3: Business Layout and Performance - Companies like Aojing Medical, Weigao Orthopedics, and Dabo Medical derive nearly 100% of their revenue from biomedical materials, indicating a focused business strategy [9] - The production and sales rates for biomedical materials are generally below 100%, with companies like Aojing Medical and Weigao Orthopedics showing lower production efficiency [11] Group 4: Strategic Planning and Innovation - Leading companies are focusing on technological innovation, market expansion, and integration of the supply chain to maintain competitive advantages [13] - Companies such as Guocera Materials and Weigao Orthopedics are investing in R&D and international market penetration to enhance their product offerings and market share [14][15]

Core Viewpoint - The recent passing of 崔福斋, a key figure in 奥精医疗, is noted, but the company asserts that this will not affect its management stability or operational independence. However, the company is facing significant challenges due to a nationwide centralized procurement policy impacting its financial performance [6][9]. Company Overview - 奥精医疗, founded in 2004 by 崔福斋, is a leading enterprise in the field of artificial bone repair materials, focusing on the research, development, production, and sales of medical devices for tissue regeneration [8]. - The company achieved a market share of 13% in the artificial bone repair materials sector in 2020 [10]. Financial Performance - In 2024, 奥精医疗 is projected to experience a revenue decline of 9.03% and a net profit decrease of 123.35%, resulting in a loss of 12.66 million yuan [6][10]. - The primary reason for this decline is the implementation of centralized procurement for orthopedic artificial bones, which has led to a significant drop in product prices and increased operational costs [10][11]. Market Dynamics - The orthopedic bone repair materials market is currently dominated by allogeneic bone, which accounts for approximately two-thirds of the market. However, legal and ethical issues surrounding allogeneic bone may enhance the market share of artificial bone repair materials [10]. - The average price reduction for orthopedic medical consumables due to centralized procurement is reported to be 74%, which has adversely affected 奥精医疗's pricing and revenue [10]. Future Outlook - 奥精医疗 is expanding its business by acquiring HumanTech Dental in 2024, which will enhance its presence in the dental implant sector [11]. - The company is also increasing its sales personnel and marketing activities, which will lead to higher sales expenses and credit impairment losses [11].

Core Viewpoint - The passing of Cui Fuzhai, the founder and actual controller of AoJing Medical, is a significant event for the company, but it is stated that his death will not impact the company's operations or management stability [1][4]. Group 1: Company Background - AoJing Medical (688613.SH) is a leading enterprise in the biomaterials industry and a listed company on the Sci-Tech Innovation Board, founded by Cui Fuzhai in 2004 [1][5]. - The company specializes in the research, development, production, and sales of implantable medical devices aimed at tissue regeneration and repair [5]. - AoJing Medical developed the mineralized collagen biomimetic bone material in 2011, which closely resembles natural human bone tissue, achieving clinical transformation and industrialization [5]. Group 2: Contributions of Cui Fuzhai - Cui Fuzhai held multiple academic and professional roles, including professor and doctoral supervisor at Tsinghua University, and was recognized as a fellow by several prestigious engineering societies [3][4]. - His research focused on biomaterials science and engineering, particularly in the areas of natural mineralization mechanisms of bones and teeth, and the development of biomimetic materials [4]. - Under his leadership, AoJing Medical has launched a series of patented products, including mineralized collagen artificial bone powder and membranes, which have been widely used in clinical settings [4][5]. Group 3: Shareholding and Succession - As of the announcement date, Cui Fuzhai directly held 6.3348 million shares of AoJing Medical, accounting for 4.62% of the total share capital, and indirectly held 354,100 shares through a partnership [1]. - The shares held by Cui Fuzhai will be subject to inheritance procedures according to legal regulations, and the company will fulfill its information disclosure obligations as necessary [1].